BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 20, 2006
 |  BioCentury  |  Tools & Techniques

Hitting the kill switch

Most pain therapies are aimed at one of three targets - opioid receptors, COX-2 or sodium channels - but all have limitations in terms of efficacy and side effects. Thus, when scientists discovered the role of nerve growth factor in pain a few years ago, several companies started programs with small molecules targeting NGF. BioXell S.p.A. is one of a handful taking a different route, having in-licensed MNAC13 from Lay Line Genomics S.p.A. last week. The humanized monoclonal antibody targets not NGF, but its receptor.

There are as yet no clinical data to demonstrate proof of concept for NGF antagonists. But the theory is that...

Read the full 528 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >